Skip to main content
. 2016 Sep 30;113(42):E6457–E6466. doi: 10.1073/pnas.1614529113

Fig. S9.

Fig. S9.

Tumors driven by NICD1 in combination with other pathways altered in prostate cancer exhibit metastatic potential. (A) Immunohistochemistry analysis of paraffin-embedded lungs from the mice injected with NICD1/kRasG12D and NICD1/Myc cells shown in Fig. 5A stained with H&E or antibodies against NICD1, pErk, Myc, and AR. (Scale bars: 100 microns in left panels; 50 microns in center and right panels.) (B) Weight of the lungs recovered at day 28 after injection from the animals shown in Fig. 5C injected with Myc-CAP-Luciferase, NICD1/kRasG12D-Luciferase, or NICD1/Myc-Luciferase was measured in milligrams and plotted. **P < 0.005, one-way ANOVA.